ANDA 78184, held by Invagen Pharms. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 78184 (Zolpidem Tartrate), held by Invagen Pharms, was first approved by FDA on Sep 7, 2007, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 7, 2007 | Original application | Approved | None posted |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Oct 26, 2022 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 22, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 3, 2008 | Supplement 2Labeling | Approved | None posted |
| May 29, 2008 | Supplement 1Labeling | Approved | None posted |
| Sep 7, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters